Special Use - Results Surveillance on Long-term Use With Wegovy®

NCT06283667 · Active, not recruiting

Last updated 2026-05-28

This trial monitored the long-term safety of Wegovy® by tracking the number of adverse reactions in adults with obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Type Observational

Participants 1,071 people

Who can join all sexes

Timeline Started 2024-06 · est. completion 2028-01

Where 112 sites · Japan

What this study is testing ClinicalTrials.gov NCT06283667 ↗

Description as written by the study sponsor.

The purpose of the study is to investigate the safety and effectiveness of Wegovy® in patients with obesity disease under real-world clinical practice in Japan. Participants will get Wegovy® as prescribed by the study doctor. The study will last for about 4 years. Participant will be in the study for about 2 years (104 weeks).

Treatments tested

Semaglutide also known as Wegovy® Drug

Paricipants will be treated with commercially available Wegovy® according to routine clinical practice at the discretion of the treating physician, following approved label in Japan. The decision to initiate treatment with commercially available Wegovy® has been made by the patient and the treating physician before and independently from the decision to participate in this study.

Main thing measured	Number of Adverse Reactions (ARs)
Sponsor	Novo Nordisk A/S
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06283667 ↗